相关实验视频

Updated: Mar 6, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

欧西默蒂尼布加达托帕马布德鲁克斯泰康在EGFR突变的先进NSCLC患者的第一线奥西默蒂尼布后进展:ORCHARD

J W Riess¹, H A Yu², X Le³

¹Internal Medicine - Hematology/Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, USA.

Annals of oncology : official journal of the European Society for Medical Oncology

|March 4, 2026

概括

奥西默蒂尼布加达托帕马布德鲁克斯泰坎在第一线奥西默蒂尼布后,在晚期EGFR突变NSCLC患者中显示出临床益处. 6毫克/千克的剂量显示出有利的益处风险概况,建议它作为首选的起始剂量.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

在ORCHARD研究中,评估了EGFR突变NSCLC在第一线 osimertinib 上进展后的新组合.
达托帕马布德鲁克斯泰坎 (Dato-DXd) 是一种被批准用于高级EGFR突变NSCLC的抗TROP2ADC.

研究的目的:

报告第二阶段ORCHARD研究模块的最终数据,该模块评估了osimertinib加Dato-DXd.
描述晚期NSCLC患者的耐药性机制和治疗结果.

主要方法:

在EGFR突变晚期NSCLC患者的II期平台研究中,患者先前接受了第一线 osimertinib.
患者接受了奥西默蒂尼布加达托-DXd,剂量为4mg/kg或6mg/kg.
主要终点:客观反应率 (ORR);次要终点:PFS,DoR,OS和安全.

主要成果:

确定的ORR为43% (4毫克/公斤) 和36% (6毫克/公斤).
平均PFS为9.5个月 (4毫克/公斤) 和11.7个月 (6毫克/公斤).
在6毫克/公斤队列中观察到较高等级≥3个副作用 (76%) 和剂量减少 (59%),其中15%患有肺炎.

结论:

奥西默蒂尼布加达托-DXd在一线奥西默蒂尼布治疗进展的患者中显示出临床益处.
尽管副作用较高,但Dato-DXd的6mg/kg剂量被建议作为首选的起始剂量,因为它具有整体的益处风险概况.
副作用可以通过预防,监测和剂量降低来控制,这与个体药物特征相一致.

关键词:

欧洲农业基金会 (EGFR) 是一个基金.在NSCLCLC中,我们可以看到.ctDNA 清除时间数据库 Deruxtecan 的数据库.分子变化 (3分/6最大)奥西米尔丁尼布 (osimertinib) 是一种

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...